Sorrento Therapeutics Inc (SRNE)

[James salmon]

$SRNEQ $SCLX On December 21, the new drug marketing application submitted by Zhaoke Oncology Drug Co., Ltd., a subsidiary of Lee's Pharmaceutical Co., Ltd., for the anti-PD-L1 monoclonal antibody socazolimab injection (Socazolimab) was approved for the treatment of recurrent or Metastatic cervical cancer. This is the sixth domestic PD-L1 monoclonal antibody and the fourth domestically produced PD-L1 monoclonal antibody approved for marketing.

Zolcazolimab (ZKAB001) was developed by the American company Sorrento. In October 2014, Lee's Pharmaceuticals introduced the development and commercialization rights of this product in Greater China.